{"id":46,"date":"2017-08-20T03:06:43","date_gmt":"2017-08-20T03:06:43","guid":{"rendered":"http:\/\/natco.tfccrk.com\/?page_id=46"},"modified":"2017-09-23T17:26:22","modified_gmt":"2017-09-23T17:26:22","slug":"products","status":"publish","type":"page","link":"https:\/\/natcopharmaasia.com\/?page_id=46","title":{"rendered":"Products"},"content":{"rendered":"
\n
\n
\n
\n
<\/div>\n
\n
ANZONAT 1mg Tablets<\/h6>\n

Active Ingredients:<\/b>\u00a0Anastrozole<\/p>\n

Strength:<\/b> 1mg<\/p>\n

Dosage Form:<\/b>\u00a0 Tablets<\/p>\n

Retail Pack:<\/b>\u00a030 tablets in a carton<\/p>\n

Indications:<\/b> Anastrozole is indicated for the treatment of advanced breast cancer in postmenopausal
\nwomen with hormone receptor positive or hormone receptor unknown locally advanced or metastatic
\nbreast cancer.<\/p>\n<\/div>\n<\/div>\n

\n
<\/div>\n
\n
LENTRONAT 2.5mg Tablets<\/h6>\n

Active Ingredients:<\/b>\u00a0Anastrozole<\/p>\n

Strength:<\/b> 1mg<\/p>\n

Dosage Form:<\/b>\u00a0 Tablets<\/p>\n

Retail Pack:<\/b>\u00a030 tablets in a carton<\/p>\n

Indications:<\/strong><\/p>\n

    \n
  • Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer.<\/li>\n
  • Extended adjuvant treatment of invasive early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy for five years.<\/li>\n
  • First-line treatment in postmenopausal women with hormone-dependent advanced breast cancer.<\/li>\n
  • Treatment of advanced breast cancer after relapse or disease progression, in women with natural or artificially induced postmenopausal endorcrine status, who have previ – ously been treated with anti-oestrogens.<\/li>\n<\/ul>\n<\/div>\n<\/div>\n
    \n
    <\/div>\n
    \n
    EMENAT 1mg Tablets<\/h6>\n

    Active Ingredients:<\/b>\u00a0Granisetron Hydrochloride<\/p>\n

    Strength:<\/b> 1mg<\/p>\n

    Dosage Form:<\/b>\u00a0 Tablets<\/p>\n

    Retail Pack:<\/b>\u00a020 tablets in a carton<\/p>\n

    Indication:<\/strong> Granisetron hydrochloride is indicated for the prevention of nausea and vomiting
    \ninduced by cytostatic therapy.<\/p>\n<\/div>\n<\/div>\n

    \n
    <\/div>\n
    \n
    XPREZA 100mg Vial<\/h6>\n

    Active Ingredients:<\/b>Azacitidine<\/p>\n

    Strength:<\/b> 100mg<\/p>\n

    Dosage Form:<\/b>\u00a0 Injectable<\/p>\n

    Retail Pack:<\/b>\u00a01 vial in a carton<\/p>\n

    Indication:<\/strong><\/p>\n